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Abstract
Background: Despite the rapid scale-up of antiretroviral therapy, virologic failure has become global public health
concern and challenge, especially in developing countries. Viral load monitoring is an important approach to
identify treatment failure and develop public health interventions in children receiving antiretroviral therapy. Thus,
this study aims to assess the magnitude and associated factors of virological failure among children on antiretroviral
therapy.
Methods: A facility-based cross-sectional study was conducted among 399 HIV-positive children on antiretroviral
therapy from 2016 to 2019 in Bahir Dar Town public health facilities. Data were extracted from children’s charts
using a standardized data extraction tool, adapted from ART intake and follow-up forms. Data were entered using
Epi-Data Version 3.1, and analyzed using SPSS Version 25. Bivariable and multivariable binary logistic regression
models were done to identify factors associated with virological failure. Variables with p-values < 0.25 were fitted
into the multivariable analysis. Finally, variables with p-values <0.05 were considered as statistically significant
factors.
Results: The period prevalence of virological failure was found to be 14.8% (95% CI: 11.5–19.3%). Opportunistic
infections (AOR = 2.19, CI: 1.13–4.25), history of treatment interruption and restart (AOR = 2.21, CI: 1.09–4.54),
younger age (AOR = 2.42, CI: 1.02–5.74), poor/fair ART adherence (AOR = 2.19, CI: 1.05–4.57), and advanced baseline
WHO clinical staging (AOR = 2.32, CI: 1.14–4.74) were found to be factors significantly associated with virological
failure.
Conclusion: The magnitude of virological failure among HIV-infected children remained high. Children with poor/
fair ART adherence, history of treatment interruption, advanced baseline WHO clinical staging, younger age, and
opportunistic infections were significantly associated with virologic failure. Thus, special attention should be given
to children who had poor/fair ART adherence and presenting with opportunistic infections.
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Background
Globally, human immunodeficiency virus (HIV) is a
major public health problem and associated with a range
of short-and long-term consequences. Approximately
1.8 million children (age < 15 years) were living with HIV
globally in 2018 [1]. Sub-Saharan Africa (SSA) suffers
from the global burden of HIV- infection, with nearly
70% of the world’s HIV/AIDS-infections and deaths oc-
curs in this region [2]. Based on Ethiopian public health
institution HIV related estimates and projections about
704,454 populations were living with HIV in 2020. Of
these 41,265 were children. Beside that 20,130 were
newly infected and 7684 were died with HIV related ill-
ness [3].
The goal of antiretroviral therapy (ART) is to suppress
viral replication and reduce HIV associated mortality
among infected children. Thus, monitoring people on
ART is important to ensure treatment success, identify ad-
herence problems, and determine whether ART regimens
should be switched in case of treatment failure (TF).
Treatment failure can be assessed in three ways: clinically,
immunologically, and virologically, which offers early and
accurate indication of treatment failure [4].
The World Health Organization (WHO) recommends
routine annual viral load monitoring for all patients on
ART, as the most accurate and preferred method to meas-
ure treatment response [4, 5]. In 2014, the Joint United
Nations Program on HIV/AIDS (UNAIDS) and partners
launched the three 90–90–90 targets, having 90% of pa-
tients on ART with VLS is the third “90” targets. Adher-
ence counseling, early detection of TF, and appropriate
switching to second-line therapy are key strengths of a
viral load monitoring [4, 6]. Likewise, the Ethiopian gov-
ernment launched different strategies, programs, and pol-
icies that provide aspiring and far-reaching goals on
prevention, treatment, health coverage, and access to af-
fordable medicine for HIV/AIDS patients like Sustainable
Development Goals (SDGs) [7]. Ethiopia has adopted the
UNAIDS 90–90-90 HIV treatment target and has devel-
oped HIV/AIDS prevention and strategic treatment plan,
which has been implemented since 2015 [5]. Ending the
AIDS epidemic by 2030 is the aim of this strategic plan in
line with the three 90’s targets.
In Ethiopia, few studies have been conducted on TF by
considering previous guidelines [8]. However, some crit-
ical factors such as HIV status disclosure, level of Hgb,
history of ART interruption, CD4 cell counts, and care-
giver’s HIV status, which contribute to VF occurrence,
were not included. Furthermore, the previous studies were
done at the referral hospitals with diverse health workers
to manage cases [8, 9]. Despite hospitals and health cen-
ters are using the same ART guidelines, this study in-
cluded health centers as they cover most health facilities
that have been giving pediatric ART services [5].
Though, different studies have been conducted on sur-
vival, ART adherence, and other aspects of HIV- infected
children, the magnitude and associated factors of VF
among children on ART has not yet been well investigated
in Ethiopia. Current and up-to-date information regarding
virological failure (VF) in HIV-positive children using rou-
tine viral load testing to measure treatment failure is es-
sential for policy makers to take appropriate actions.
Therefore, the findings of this study will highlight the
prevalence and associated factors of VF with implications
to improve health workers’ interventions, to ensure treat-
ment cost-effectiveness, and to accelerate the reduction of
HIV related morbidity and mortality of children.
Methods
Study settings, design, and period
A health facility-based cross-sectional study was carried
out from February to March 2020 among HIV-infected
children on ART between September 2016 and Decem-
ber 2019. In Ethiopia, chronic HIV/AIDS care and treat-
ment services are provided at hospital and health center
settings throughout the country. This study was con-
ducted in Bahir Dar town public health facilities, which
is 565 km away from Addis Ababa. The study was con-
ducted in four selected public health facilities (i.e. Bahir
Dar Health Center, Abay Health Center, Han Health
Center, and Felege Hiwot Comprehensive Specialized
Hospital).
Study participants, sample size, and sampling technique
All HIV-infected children (aged < 15 years) taking ART
in Bahir Dar Town public health facility were the target
population. All HIV-infected children who took ART at
least for 9 months with documented viral load test re-
sults were included. Conversely, children with incom-
plete medical records (i.e. age of child at ART initiation,
baseline ART regimen, current CD4 cell counts and un-
known outcome status) were excluded.
The minimum required sample size was determined
using a single population proportion formula. To com-
pute the sample size, the following statistical assump-
tions were considered: - prevalence of VF =50% because
there was no published study done on this topic in
Ethiopia, margin of error = 5% and the value of Zα/2 =
1.96, which is the corresponding Z score of 95% confi-
dence interval (CI).
n ¼ Za=2ð Þ
2p 1 − pð Þ
dð Þ2 ¼
1:96ð Þ2 0:5 1 − 0:5ð Þ
0:05ð Þ2 ¼ 384:16
 385
Where, n = the required sample size, Zα/2 = Standard
normal variation for type 1 error, p = prevalence (0.5) &
d =Margin of sampling error tolerated (0.05).
Gelaw et al. Italian Journal of Pediatrics           (2021) 47:84 Page 2 of 9
The calculated sample size was 385. By considering a
10% contingency rate for incomplete charts, the final
minimum required sample size of this study was 424
medical records.
This study was conducted in three randomly selected
health centers, and one purposively (because it has high
patient flow and case-team composite) selected compre-
hensive specialized hospital. First, a sampling frame was
prepared based on the patient’s medical registration
number (MRN) from each health facility’s recorded doc-
uments. The total sample sizes were then allocated for
each healthy facility proportionally to the number of
population size. Finally, medical charts of HIV-infected
children taking ART at the selected public health facil-
ities were sorted and selected using a simple random
sampling technique (Fig. 1).
Data extraction procedure
Available information from patient’s chart was extracted
using structured checklist, prepared in English. The data
extraction checklist was adapted from the Ethiopian Fed-
eral Ministry of Health ART clinic intake and follow-up
forms and included socio-demographic, clinical, labora-
tory, and treatment-related characteristics. Data were ex-
tracted by trained health professionals through
document review. Five ART trained nurses were re-
cruited as data collector. Orientation about the objec-
tives of the study, contents of the tool, and data
extraction procedures was given for data collectors and
supervisors for 1 day. The assigned supervisors and prin-
cipal investigator closely monitored the whole data col-
lection process. Besides, the consistency between
collected data and medical records was checked using
randomly selected reviews of previously extracted charts.
Measurements
Virologic failure
Was diagnosed when the viral load above or equal to
1000 copies/ml under ART based on two consecutive
VL results 3 months apart, with adherence support fol-
lowing the first viral load test after at least 6 months of
ART [5].
Adherence
Was defined as “good”, “fair” or “poor” if the patient
took ≥95% (missing one from 30 doses or two out of 60
doses), 85–94% (missing 2–4 doses out of 30 doses or
4–9 from 60 doses) or <85% (missing ≥5 doses from 30
doses or > 10 from 60 doses), respectively of monthly
doses [4].
Malnutrition
Was diagnosed when HIV-positive child has one of the
following forms of malnutrition: Height/Age < − 2, or
Weight/Age < − 2, or Weight/Height < − 2 standard devi-
ation based on the WHO curve [10].
Fig. 1 Schematic presentation of sampling procedure to assess the magnitude and associated factors of virological failure among children on
ART in Bahir Dar Town public health facility ART clinics (2016–2019), North-west Ethiopia, 2020. Footnote: proportion was calculated using the
formula ni ¼ Ni ðnNÞ as follows: our calculated sample size (424) multiplied by the total number of HIV-infected children on ART at each health
facility between 2016 and 2019 (Ni), then divided by the total number of HIV-infected children (N) in the selected public health facilities. For
example, for AHC, it was calculated as: 81*424/681 = 50
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Treatment interruption
Was defined as a treatment interruption for at least 1
week during the previous 6 months.
Data management and statistical analysis
Data were entered into Epi Data Version 3.1 and
exported to Statistics Package for Social Science (SPSS)
Version 25 for further analysis. Tables were used to
present descriptive results. Additionally, frequencies,
percentages, proportions, and summary statistics (mean,
median) were used to summarize the study population
characteristics. Variables with p-values < 0.25 in the
bivariable analysis were entered into the multivariable
analysis to control the effects of confounders. Goodness
of fit of the model was checked using Hosemer-
Lemeshow goodness of fit test. In the multivariable ana-
lysis, variables with p-values less than 0.05 were consid-
ered as statistically significant factors. Lastly, odds ratios
with their correspondence 95% CIs were used to assess
the strength and the direction of association.
Results
Socio-demographic characteristics of the participants
After reviewing 424 HIV-infected children’s charts, 399
charts were included and 25 charts were excluded (six
charts missed, and 19 charts had incomplete data) in the
final analysis. The medical record retrieval rate was
94.1%. More than half (62.4%) of the study participants
were recruited from Felege Hiwot Comprehensive Spe-
cialized Hospital. The mean age of children at ART initi-
ation was 6.66 years (SD: ±3.49). Majority (82%) of the
children were from Bahir Dar Town. Nearly half of the
respondents (48.6%) were females (Table 1).
Clinical, laboratory, and ART information
About 15% of the study participants were taking ART
for less than 25months, and the mean duration on ART
was 57.76 months (SD: ±25.81). Majority (83%) of the
participants had good level of ART adherence. Regarding
nutritional status, only 7% of the children were malnour-
ished. Of these 25% were severely malnourished. More
than half (61.7%) of the children had CD4 counts
≥350 cells/mm3, with a median of 453 (IQR: 288–
735) cells/mm3. More than half (52.1%) of the chil-
dren were taking nevirapine-based ART drugs. Add-
itionally, about 14.5% of the children were anemic
(Hgb < 10 mg/dl). Nearly, 16.5% of the participants
restarted ART after treatment interruption. Further-
more, almost 81% of the participants had history of
regimen change due to different reasons. Lastly, most
(82.5%) of the participants were classified as WHO
clinical stage I/II at ART initiation (Table 2).
Magnitude of virological failure
A total of 59 HIV-infected children had a virological fail-
ure, verified through record review. The overall magni-
tude of virologic failure among HIV-infected children
was found to be 14.8% (95% CI: 11.5, 19.3%). Most
(90%) of the VF occurred after 25 months of ART
initiation.
Factors associated with virological failure
In the multivariable logistic regression analysis, poor
ART drug adherence level, treatment restart after the
interruption, younger age at ART initiation, history of
opportunistic infections, and advanced baseline WHO
clinical staging (stage III and IV) were factors signifi-
cantly associated with the occurrence of virologic failure.
Accordingly, the odds of virological failure among chil-
dren classified as WHO clinical stage III and IV was 2.3
times more likely (AOR = 2.3, 95% CI: 1.1–4.7) com-
pared to their WHO clinical stage I and II counterparts.
Moreover, the odds of virological failure among children
who had opportunistic infections during follow-up was
two times higher as compared to those who did not have
OIs (AOR = 2.2,95% CI: 1.1–4.3). Similarly, the odds of
virological failure among younger age (age ≤ 5 years) was
2.4 times higher odds (AOR = 2.4, 95% CI: 1.0–5.7) com-
pared to older age children (age 10–15 years). The odds
of virological failure was 2.2 times higher (AOR = 2.2,
95% CI: 1.1–4.5) among children who had history of
treatment interruption compared with those who did
not have history of treatment interruption. Finally, the
odds of virological failure among participants who had
poor/fair ART adherence level was 2.2 times higher
(AOR = 2.2, 95% CI: 1.1–4.6) compared to those who
had good ART adherence level (Table 3).
Discussion
This facility-based cross-sectional study found that the
magnitude of virological failure among HIV-infected
children was 14.8% (95% CI: 11.5–19.3%). This finding is
in line with the magnitude of virological failure reported
from Ghana (15.7%%) [11], South Africa (19.3%) [12],
and Malawi (16%) [13]. Conversely, this finding is lower
than studies conducted in Cameroon (30.6%) [14], Kenya
(43.1%) [15], Tanzania (25.4%) [16], and Malawi (66%)
[17]. The possible sources of variation in the prevalence
rate of virological failure might be due to the differences
in sample size, study period, the variability in virological
failure measurements, and the difference in diagnostic
capacity. As an example, a Tanzanian study included
only 206 participants. Regarding variability in virological
failure measurements, a studies done in Malawi and
Cameroon used a single plasma viral load above 1000
copies/ml, and 200copies/ml to diagnose virological fail-
ure respectively [14, 17], whereas this study used two
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consecutive plasma viral load 1000 copies/ml and above.
The other possible justification for the discrepancy could
be due to the difference in study period as there were
changes in treatment guidelines over time. An additional
possible explanation might be the difference in diagnos-
tic capacity between study settings or different methods
used to retrieve and analyze it.
We found that different factors were significantly asso-
ciated with the occurrence of virological failure. In this
regard, younger ages (age ≤ 5 years) were more prone to
develop virologic failure. This finding is in agreement
with other previous studies done in Swaziland [18], Afri-
can and Asian children [19], Tanzania [20], and
Zimbabwe [21]. This could be explained by the fact that
children initiating ART at their younger age are more
likely to have an immature immune system, which
causes rapid disease progression contrasted with a com-
parative group [22]. Additionally, HIV-status disclosure
is the most important factor for positive treatment out-
comes [23, 24]. However, in our study, HIV-status dis-
closure among children aged less than 10 years was very
low. Furthermore, unlike younger children, older chil-
dren might have the opportunity to get information
about HIV/AIDS in school, enabling them to adhere to
their treatment. On the other hand, in younger children,
their drug has mainly been given by caregivers, and they
could miss it.
However, this finding contradicts with researches done
in Cameroon [14], and Tanzania [25] suggesting that
older age at ART initiation was significantly associated
with high virological failure. The possible explanation
for the above noted differences could be due to the
Table 1 Socio-demographic characteristics of the caregivers and study participants in Bahir Dar Town, North western Ethiopia, 2020
(n = 399)
Variables Category Frequency(n) Percentage (%)
Age 0–5 years 157 39.3
6–9 years 147 36.8
10–15 years 95 23.8
Sex Female 194 48.6
Male 205 51.4
Place of residence Bahir Dar 327 82.0
Outside of Bahir Dar 72 18.0
Type of health facility Hospital 249 62.4
Health centers 150 37.6
Age of caregivers 20–40 years 320 80.2
> 40 years 79 19.8
Caregivers occupation (n = 380) Government employed 85 21.3
Housewife 129 32.3
Merchant 96 24.1
Daily laborer 37 9.3
Others 33 8.3
Parent status Both alive 256 64.2
Mother died but, father alive 49 12.3
Father died but, mother alive 53 13.3
Both died 22 5.5
Not recorded 19 4.8
Relationship Parent 364 91.2
Grandparent 18 4.5
Others 17 4.3
Caregiver’s HIV Status Negative 63 15.8
Positive 303 75.9
Not recorded 33 8.3
Child’s HIV status disclosure Disclosed 281 70.4
Not disclosed 118 29.6
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differences in inclusion criteria. For example, a study
done in Cameroon included participants age lower than
18 years, whereas our study included children under 15
years.
This study also revealed opportunistic infections dur-
ing follow-up were strongly associated with the occur-
rence of virological failure. This result is concordant
with other reports from Tanzania [20] and Kenya [26],
which demonstrated that co-morbidities such as TB
(one of the opportunistic infections) were associated
with the occurrence of virological failure. This is well-
known that co-morbidities such as TB weaken the im-
mune system among patients and rapidly increase HIV
disease progression to its advanced stage. Additionally,
although ART needs a lifelong commitment for its ef-
fectiveness, HIV-related co-morbidities could prohibit
patients from getting their regular ART follow-up and
treatment intake. There is an inverse linkage between
viral replication and the efficiency of the immune sys-
tem, resulting in acquiring virological failure [5, 27].
Table 2 Clinical and treatment-related characteristics of the study subjects at ART initiation and during follow up in Bahir Dar Town
public health facilities, Northwestern Ethiopia, 2020(n = 399)
Variables Category Frequency(n) Percentage (%)
History of malnutrition No 371 93.0
Yes 28 7.0
Severity of malnutrition Mild 9 32.1
Moderate 12 42.9
Sever 7 25.0
Baseline CD4 counts (n = 383) < 350cells/mm3 137 34.3
≥ 350cells/mm3 246 61.7
Baseline hemoglobin level(n = 380) < 10 mg/dl 58 14.5
≥ 10 mg/dl 321 80.5
Duration on ART < 25 months 61 15.3
≥ 25 months 338 84.7
Baseline WHO clinical staging Stage I/II 329 82.5
Stage III/IV 70 17.5
WHO clinical staging in last follow up Stage I/II 378 94.7
Stage III/IV 21 5.3
Presence of opportunistic infections No 272 68.2
Yes 127 31.8
History of IPT No 257 64.4
Yes 142 35.6
History of CPT No 196 49.1
Yes 203 50.9
ART regimen given at first Nvp based 208 52.1
Efv based 162 40.6
Others 29 7.3
Regimen change No 77 19.3
Yes 322 80.7
History of ART interruption and restart No 333 83.5
Yes 66 16.5
Baseline developmental status for age <5 years (n = 157) Appropriate 138 87.9
Regression 4 2.5
Delay 15 9.6
Baseline functional status for age≥ 5 years(n = 242) Working 189 78.1
Ambulatory 48 19.8
Bed Ridden 5 2.1
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Finally, HIV-infected children with co-infections are at
high risk for drug burden and drug-drug interactions
which might lead to poor ART adherence and treatment
failure, especially anti- TB- drugs [28].
History of ART treatment interruption/discontinu-
ation was also significantly associated with the occur-
rence of virological failure. This is because ART
suppresses the viral replication resulting in boosting the
patient’s immunity, decreasing the incidence of OIs, and
reducing the viral load [29]. Moreover, as ART helps
boost HIV-infected individuals’ immunity, drug inter-
ruption could be associated with a decreased efficiency
of the immune system and increased drug resistance
risk. As a result, patients lose their ability to suppress
viral replication and reduce viral load, finally leading to
virological failure [30, 31]. In addition, this is due to the
fact that interruption of antiretroviral therapy (ART),
opportunistic infection, and WHO clinical stage are
Table 3 Bivariable and multivariable logistic regression analysis of factors associated with virological failure among HIV positive
children in Bahir Dar Town public health facility ART clinics, Northwestern Ethiopia, 2020 (n = 399)
Factors Virological failure,n (%) COR(95% CI) AOR(95% CI)
Yes No
Age
0–5 years 34 (21.7) 123 (78.3) 2.35 (1.10–5.01) 2.42 (1.02–5.74)**
6–9 years 15 (10.2) 132 (89.8) 0.97 (0.42–2.25) 1.04 (0.42–2.58)
10–15 years 10 (10.5) 85 (89.5) 1 1
Sex
Male 35 (17.1) 170 (82.9) 1.46 (0.83–2.56) 1.27 (0.68–2.36)
Female 24 (12.4) 170 (87.6) 1 1
Place of residence
Outside of Bahir Dar 14 (19.4) 58 (80.6) 1.51 (0.78–2.94) 1.80 (0.84–3.86)
Bahir Dar 45 (13.8) 282 (86.2) 1 1
Type of health facility
Health-center 27 (18) 123 (82) 1.49 (0.85–2.60) 1.69 (0.89–3.22)
Hospital 32 (12.9) 217 (87.1) 1 1
Child’s HIV status disclosure
Not disclosed 23 (19.5) 95 (80.5) 1.65 (0.93–2.93) 0.85 (0.42–1.72)
Disclosed 36 (12.8) 245 (87.2) 1 1
Baseline WHO clinical Staging
Stage III/IV 21 (30) 49 (70) 3.28 (1.78–6.06) 2.32 (1.14–4.74)**
Stage I/II 38 (11.6) 291 (88.4) 1 1
Opportunistic infection
Yes 33 (26) 94 (74) 3.32 (1.89–5.85) 2.19 (1.13–4.25)**
No 26 (9.6) 246 (90.4) 1 1
WHO clinical Staging (last visit)
Stage III/IV 7 (33.3) 14 (66.7) 3.14 (1.21–8.13) 1.36 (0.44–4.16)
Stage I/II 52 (13.8) 326 (86.2) 1 1
Regimen change/substitute
Yes 51 (15.8) 271 (84.2) 1.62 (0.74–3.58) 1.53 (0.63–3.72)
No 8 (10.4) 69 (89.6) 1 1
Interruption and restart
Yes 18 (27.3) 48 (72.7) 2.67 (1.42–5.03) 2.21 (1.09–4.54)**
No 41 (12.3) 292 (87.7) 1 1
ART adherence
Fair/Poor 20 (29.4) 48 (70.6) 3.12 (1.68–5.80) 2.19 (1.05–4.57)**
Good 39 (11.8) 292 (88.2) 1 1
Duration on ART
≥ 25 months 53 (15.7) 285 (84.3) 1.71 (0.70–4.16) 2.17 (0.81–5.86)
< 25 months 6 (9.8) 55 (90.2) 1 1
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highly interrelated risk factors for treatment failure. As
patients interrupt regular follow-up and discontinue tak-
ing drugs, their immune status becomes compromised.
This implies, there is a high chance of acquiring oppor-
tunistic infections and increase the rate of viral replica-
tion as well, which leads to disease progress/advanced
clinical stage and virological failure [29, 32].
This study also found that children classified as ad-
vanced WHO clinical staging (stage III and IV) were
more likely to develop virological failure. This finding is
in agreement with studies reported from Uganda [33]
and Swaziland [18]. This might be due to the fact that
children presenting with advanced WHO clinical stage
at ART initiation are at higher risk of OIs, especially TB.
The presence of OIs during ART initiation increase pill
burden, which results in drug-drug interactions, and ul-
timately leads to treatment failure and early mortality.
Studies suggested that HIV-infected individuals treated
with anti-TB medications usually experience drug tox-
icity as compared to HIV-uninfected individuals [34, 35].
Finally, children who had fair/poor ART adherence
level were also positively associated with virological fail-
ure. This finding is supported by studies conducted in
Uganda [33], Tanzania [36], and Gabon [30]. If HIV-
infected individuals failed to take their medication regu-
larly and daily, they are at higher risk to developing drug
resistance. This resulted in experience virological failure
[29].
Limitations
This study has some limitations that must be considered
before interpreting results. Since the study was based on
secondary data, some important variables (such as edu-
cational level and income) were missed. Thus, there
might be information bias because of underreporting/
missing data elements. There could also be selection bias
during data collection as individuals with incomplete
medical records were excluded. As the study used cross-
sectional study design, it did not establish the possible
cause and effect relationship between dependent and in-
dependent variables.
Conclusion
This study demonstrated that, there was a high magni-
tude of virological failure among HIV positive children
compared to the current Ethiopian ART guidelines tar-
get (not more than 10%). Children with poor/fair ART
adherence level, history of ART treatment interruption,
advanced baseline WHO clinical staging (stage III and
IV), younger age, and opportunistic infections were
found to be factors significantly associated with the oc-
currence of virological failure.
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